Preclinically, combination therapy with epacadostat and anti-CTLA-4 or anti-PD-1/PD-L1 improved tumor control and increased IL-2 production and CD8 T-cell proliferation in murine melanoma better than single agent therapy [29]. Here, IL2 is linked to melanoma.